Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Rates of block‐related adverse events · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Adverse events ‐ Phosphate > 7.0 mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events (spotting at 3 and 6 months) · women with uterine fibroids
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: dry mouth · Adults with overactive bladder (OAB)
Anticholinergics may leads to higher adverse events: dry mouth compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (vomiting) · children aged less than 6 months with acute diarrhoea
The intervention probably leads to higher adverse events (vomiting) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events (vomiting) · children with persistent diarrhoea
It is very uncertain whether the intervention changes adverse events (vomiting) (very low certainty).
1 finding from 1 review